Where Are They Now · Profile 06

Janet Woodcock

Janet Woodcock at a congressional hearing as Acting FDA Commissioner

Longtime head of the FDA’s drug center, Operation Warp Speed’s therapeutics lead, and Acting FDA Commissioner during the 2021 vaccine rollout — named throughout the film as the official who steered BARDA toward the hospital-only hydroxychloroquine authorization.

Claims are labeled Documented, Allegation, Open question or Gap (something the public record does not yet show). An allegation or open question is not a finding of wrongdoing. Woodcock has not been charged with or sanctioned for anything, and a bad policy call is not fraud. She does not appear on camera in Epidemic of Fraud; the photo above is from a congressional hearing during her time as Acting Commissioner.

Who she was in the COVID era

  • Director of the FDA’s Center for Drug Evaluation and Research (CDER) for more than 20 years, after earlier senior roles at the biologics center (CBER). Documented Source: Friends of Cancer Research (Jan. 21, 2025)
  • In May 2020 she stepped away from CDER to lead therapeutics for Operation Warp Speed; Patrizia Cavazzoni became acting CDER director. Documented Sources: HHS Operation Warp Speed announcement (May 15, 2020, archived); BioCentury
  • Acting FDA Commissioner, January 2021 – February 2022 (the vaccine-rollout year), then Principal Deputy Commissioner, February 2022 – February 2024. Documented Sources: Alliance for Aging Research (Oct. 9, 2024); FDA bio page
  • Hydroxychloroquine at FDA while she ran CDER: an Emergency Use Authorization for Strategic National Stockpile hydroxychloroquine/chloroquine in certain hospitalized patients, issued at BARDA’s request (Mar. 28, 2020); an FDA safety communication cautioning against use outside the hospital setting or a clinical trial (Apr. 24, 2020); and revocation of the EUA at BARDA’s request (Jun. 15, 2020). Documented These were agency actions; her personal role in each is not shown in the public documents we reviewed. Open question Sources: FDA EUA letter (Mar. 28, 2020); FDA Drug Safety Communication; FDA revocation

In the film

  • Woodcock is named in 23 caption lines, mainly chapter 30, “Rick Bright & Janet Woodcock Block Early HCQ Use” (01:19:15), chapter 32 on John’s FOIA request (01:22:07), and chapter 49, “My Final Email to Janet Woodcock” (01:52:09). Documented (what the film shows)
  • Citing Rick Bright’s whistleblower complaint, the film says that on March 24, 2020 Woodcock “strongly recommended that BARDA submit an application for an EUA instead of an expanded Access IND protocol” (01:19:24). Documented (quote from Bright’s complaint)
  • Narration: “The idea to deny early treatment came from the FDA” (01:19:38). Dr. Robert Malone, in a clip: “The conspiracy between Janet Woodcock and Rick Bright…” (01:24:53). Allegation (the film’s argument about intent)
  • Bright, under oath: “I trust Dr Woodcock and her scientific judgment immensely” (01:14:29). Documented (what the film shows)
  • Full timecodes are in the annotated transcript.

COVID-era money

  • No personal COVID-era payment found — no prize, book deal, PPP loan or royalty stream comparable to the Emanuel, Fauci or Collins profiles. Documented (absence in our review so far — not proof there is none)
  • As a senior FDA official she filed public financial disclosures (OGE Form 278e), which would show outside income, holdings and any post-employment agreements. We have not yet obtained her 2020–2023 filings. Gap

Seats since leaving FDA (2024–2026)

  • Adviser to the Haystack Project, a rare-disease coalition (April 2024). She told the Pink Sheet she would keep FDA and industry “at arm’s length.” Documented Source: Pink Sheet / Citeline (Apr. 17, 2024)
  • Board of the Alliance for Aging Research (October 2024), appointed alongside GSK’s head of government affairs. Documented Source: Alliance for Aging Research
  • Board of Friends of Cancer Research (Jan. 21, 2025). Documented Source: Friends of Cancer Research
  • Board of Quantum Leap Healthcare Collaborative, an adaptive-trial nonprofit behind the I-SPY trials (Apr. 24, 2025). Documented Source: GlobeNewswire (Apr. 28, 2025)
  • Advisory board of Nortiva Bio, a new for-profit Innoviva subsidiary (Jun. 18, 2026). Fierce Biotech reports the Gates Foundation gave a $5 million grant to Nortiva’s lead contraceptive program — a grant to the company, not a payment to Woodcock. Documented Source: Fierce Biotech (Jun. 18, 2026)
  • Pay for any of these seats has not been disclosed. Gap
  • Friends of Cancer Research and the Alliance for Aging Research take industry funding. Whether a former top drug regulator joining such boards is a revolving-door concern is a fair question; it is not a finding of wrongdoing. Open question

Consequences

  • No legal, regulatory or professional sanction found. She retired on her own schedule. Documented (absence of a record, as of October 2026)
  • Retirement timing. FDA Commissioner Robert Califf announced her retirement on Nov. 16, 2023, effective early 2024; she left in February 2024. Documented Source: Reuters (Nov. 16, 2023) The film says John emailed her in November 2023, she replied “no comment,” and her retirement was announced eight days later (01:52:16–01:54:18). The dates line up; any causal link is the film’s implication. Allegation (causation)
  • Passed over for permanent commissioner (2021). Sen. Joe Manchin publicly urged President Biden not to nominate her, citing FDA opioid approvals during her years running CDER. Biden nominated Robert Califf instead. She later said the FDA “miscalculated” on OxyContin. Documented Sources: Endpoints News; The Guardian (Jan. 28, 2021); Bloomberg Law
  • The film (01:22:38) says she was “directly involved in the approval of all of the opioids including OxyContin and Fentanyl over the last 25 years.” What the record shows is that she led the FDA drug center during most of those approvals — the basis of Manchin’s criticism. “All” and “directly involved” are the film’s framing. Allegation
  • Aduhelm (2021, while she was Acting Commissioner). On Jul. 9, 2021 she asked the HHS Inspector General to review contacts between FDA staff and Biogen. A December 2022 joint staff report of the House Oversight and Energy & Commerce committees called FDA’s review of the Alzheimer’s drug “atypical.” That finding concerns the agency, not COVID, and is not a sanction on her personally. Documented (context) Sources: CNN (Jul. 9, 2021); House joint staff report (Dec. 29, 2022)
  • The film (01:22:52) says she was “on the editorial board of the New England Journal of Medicine when it published the fraudulent Surgisphere study.” We have not confirmed an editorial-board seat. What is documented: she co-wrote NEJM’s 2016 “Clinical Trials Series” editorial with editor-in-chief Jeffrey Drazen and James Ware. Open question Source: NEJM, “Clinical Trials Series” (Jun. 2, 2016) (On the Surgisphere study, see Sapan Desai.)
  • The film (01:23:11) says the FDA under Woodcock worked to restrict quinine for “at least 27 years,” a reference to the agency’s 1990s action against over-the-counter quinine for leg cramps. Her personal role is not shown in the record we reviewed. Allegation
  • FOIA trail: America First Legal’s lawsuit against HHS (D.D.C. 1:23-cv-03680) produced interim releases, through at least May 14, 2025, of Woodcock, Bright, Disbrow and Hinton records mentioning hydroxychloroquine, early treatment or remdesivir — the communications John asked the FDA for in the film (01:22:12). We have not yet reviewed them. Open question Sources: HHS litigation releases (America First Legal); 13th interim response (Apr. 15, 2025)

Where is she now

  • Retired from the FDA (February 2024). She sits on the boards of the Alliance for Aging Research, Friends of Cancer Research and Quantum Leap Healthcare Collaborative, on Nortiva Bio’s advisory board (June 2026), and advises the Haystack Project. Documented (sources above)

What the record does not show yet

  • Her OGE 278e financial disclosures for 2020–2023 and her termination report: outside income and holdings. Gap
  • Compensation for her board and advisory seats (nonprofit Form 990s for 2024–2025; Nortiva is private). Gap
  • What the America First Legal FOIA releases show about the March 24, 2020 Woodcock–Bright exchange and hydroxychloroquine emails. Gap
  • Whether she held an NEJM editorial-board seat in 2020. Gap
  • The Federal Register notice behind the film’s quinine claim, and her role in it. Gap

Last reviewed October 2026. This profile is updated as new records surface. Corrections: Press@EpidemicOfFraud.com

← All profiles